N-acetylcysteine (NAC) for methamphetamine dependence: A randomised controlled trial
Rebecca McKetin, Olivia M Dean, Alyna Turner, Peter J Kelly, Brendan Quinn, Dan Lubman, Paul Dietze, Gregory Carter, Peter Higgs, Barbara Sinclair, David Reid, Amanda L Baker, Victoria Manning, Nina te Pas, Tamsin Thomas, Ramez Bathish, Dayle K Raftery, Anna Wrobel, Lucy Saunders, Shalini Arunogiri Show all
ECLINICALMEDICINE | ELSEVIER | Published : 2021
Background: Methamphetamine dependence is a significant global health concern for which there are no approved medications. The cysteine prodrug, N-acetylcysteine (NAC), has been found to ameliorate glutamate dysregulation in addiction, and to reduce craving for methamphetamine and other drugs. We evaluated the efficacy and safety of NAC as a pharmacotherapy for methamphetamine dependence. Methods: A parallel double-blind randomised placebo-controlled trial of people dependent on methamphetamine recruited from Geelong, Melbourne and Wollongong, Australia, between July 2018 and December 2019. Participants were randomised to receive either 12 weeks of oral NAC (2400 mg/day) or matched placebo, ..View full abstract
Awarded by Australian NHMRC
This research was funded by the Australian NHMRC (Project Grant No. 1128147) .